NGF and NGF-receptor expression of cultured immortalized human corneal endothelial cells by Sornelli, Federica et al.
NGF and NGF-receptor expression of cultured immortalized
human corneal endothelial cells
Federica Sornelli,1 Alessandro Lambiase,2 Flavio Mantelli,2 Luigi Aloe1
1Institute of Neurobiology and Molecular Medicine, Department of Neurobiology, National Research Council (CNR), Rome, Italy;
2Department of Ophthalmology, University Campus Bio-Medico, Rome, Italy
Purpose: Several growth factors, including nerve growth factor (NGF) and vascular endothelial growth factor (VEGF),
play an important role in the homeostasis of the ocular surface. The involvement of both these growth factors in the
pathophysiology of intraocular tissues has been extensively investigated. Despite the expression of NGF receptors by
corneal endothelium, to date the role of NGF on the endothelial cell remains to be determined. Using a clonal cell line of
human corneal endothelial cells, the aim of this study was to investigate the expression of the NGF-receptor and the
potential partnership of NGF and VEGF in maintaining cell viability in vitro.
Methods: A human endothelial cell line (B4G12), was cultured under serum-free conditions as previously described with
and without addition of different concentrations of NGF, anti-NGF-antibody (ANA), or VEGF for 4 days and these cells
were used for immuno-istochemical, biochemical, and molecular analyses.
Results: NGF induces overexpression of NGF-receptors and synthesis and release of VEGF by endothelial cells and these
cells are able to produce and secrete NGF.
Conclusions: These observations indicate that human corneal endothelial cells are receptive to the action of NGF and
that these cells may regulate NGF activity through autocrine/paracrine mechanisms.
Degeneration  of  corneal  endothelial  cells  is  a  critical
pathogenetic  event  of  a  wide  number  of  ocular  surface
diseases,  from  congenital,  to  inflammatory,  immune  and
degenerative. The result of an altered corneal endothelium
function  is,  inevitably,  a  progressive  loss  of  corneal
transparency leading to blindness. Therefore, once the total
count of endothelial cells is not sufficient to warrant corneal
transparency, surgical intervention with a corneal transplant
is  currently  the  only  option  available,  since  corneal
endothelial cells do not have the ability to proliferate. Several
growth factors present in the anterior chamber of the eye have
been  investigated  for  their  potential  role  in  supporting
endothelium  survival  and  function.  Nerve  growth  factor
(NGF) is the first discovered and best-characterized member
of the neurotrophin family [1]. It is produced by and acts upon
cells of the visual system, both in vitro and in vivo and it is
able to promote the functional recovery of retinal ganglion
cells  (RGCs)  in  an  animal  model  of  ocular  ischemia  and
following optic nerve section, to reduce retinal cell damage
induced by intraocular hypertension and to delay retinal cell
degeneration in rodents with retinitis pigmentosa [2-7]. These
effects are mediated by two NGF-receptors, the high-affinity
receptor tyrosine kinase (TrkA), and the low-affinity receptor
p75 neurotrophin receptor (p75), both located on the surface
of  NGF-responsive  cells.  Altered  expression  of  these
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receptors and/or their ligands can lead to NGF-target cell
degeneration  [8].  NGF  is  present  in  the  aqueous  humor,
increases following ocular injuries, and binds to its specific
receptors expressed by the corneal endothelium. It has also
been demonstrated that topical NGF eye drops administration
promotes corneal healing and exerts anti-inflammatory and
immunomodulatory  actions  on  corneal  endothelial  cells
[9-11].  Another  growth  factor  that  has  been  extensively
investigated in the last years for its effects in modulating
ocular  immune  and  healing  processes  is  the  vascular
endothelial growth factor (VEGF). VEGF is an endogenous
biologic mediator that is released by endothelial cells and is
known to play a pivotal role on ocular disorders and corneal
vascularization [12-18]. Recent studies have shown that NGF,
like VEGF, possesses angiogenic and neurotrophic action and
is  able  to  activate  an  intracellular  signaling  cascade  in
endothelial cells, the Ras/extracellular signal-regulated kinase
(Ras/ERK)  and  phosphatidylinositol  3-kinase-dependent
(P13/Akt)  pathways,  involved  in  the  survival  and  in  the
modulation  of  angiogenic  activity  [19,20].  Moreover,
previous studies have also indicated that VEGF plays a role
in mediating corneal nerve repair and the detrimental effects
of anti-VEGF drugs on the ocular surface are mediated by a
down regulation in NGF levels [21,22]. These observations
and recent evidence that NGF gene transfer to the corneal
endothelium  modulates  endothelium  survival  through  the
inhibition of immune reactions triggered us to investigate the
physiologic role of NGF on corneal endothelium survival both
directly through binding to its receptors, and/or indirectly
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1439through  VEGF  [11].  The  aim  of  the  present  study  was,
therefore, to investigate the effect of NGF in an in vitro human
corneal  endothelial  cell  line  that  displays  several
characteristics of in vivo human endothelial cells [23].
METHODS
Chemicals:  NGF,  anti-mouse  NGF-antibody  and  VEGF
(Sigma-Aldrich, St. Louis, MO) were used for cell treatment.
Purified NGF was isolated from mouse submandibular gland
following the method of Bocchini and Angeletti [24]. The
anti-mouse  NGF  antibody  was  prepared  in  rabbits  and
purified  by  affinity  chromatography  and  characterized  as
described in another study [25]. Polyclonal rabbit anti-trkA
(1mg/ml;  diluted  1:50;  Up  State,  Temecula,  CA),
monoclononal  mouse  anti-VEGF  (1mg/ml;  diluted  1:50;
Santa Cruz Biotechnology, CA), monoclonal mouse anti-p75
(clone 192; diluted 1:10) purified in our laboratory [26] and
biotinylated  goat  anti-rabbit  or  horse  anti-mouse  IgG
(Vectastain  Elite  ABC  Kit;  Vector  Laboratories,  Inc.
Burlingame,  CA)  using  the  procedure  suggested  by  the
manufacturer were used for immunocytochemistry, while the
goat anti-rabbit 594 or anti-mouse 488 IgG antibody Alexa
Fluor (diluted 1:250; Invitrogen, Eugene, OR) and Hoechst
33258 (5 μg/ml; Sigma-Aldrich, St. Louis, MO) were used for
immunofluorescence.
Cell line and cell culture: A clonal cell line (B4G12) of human
corneal  endothelial  cells  (HCEC),  indicated  thereafter  as
HCEC, was kindly obtained by Dr. Monica Valtink, from the
Institute of Anatomy, Medical Faculty, Technishe Universitat
Dresden, Germany. Cells were cultured in complete medium
in T25 culture flasks coated with 1 mg chondroitin-6-sulfate
(from  shark  cartilage;  Sigma-Aldrich)  and  10  μg  laminin
(Sigma-Aldrich) as suggested [27]. At confluence, cells were
removed using trypsin/EDTA (0.05%/0.02%) and enzyme
activity quenched by proteinase inhibitor cocktail [23]. For
our studies, cells were cultured on T25 culture flasks pre-
coated as previously described in serum-free medium Human
Endothelial-SFM  (GIBCO-Invitrogen  Carlsbad,  CA)
supplemented  with  10  ng/ml  human  recombinant  basic
fibroblast growth factor (bFGF) (Sigma-Aldrich). Cells were
seeded at a density of ~8,000 cells/cm2 with or without NGF,
anti-NGF  antibody  (ANA),  or  VEGF  at  different
concentration and counted 4 days later. Cells were removed
with Trypsin/EDTA solution (Sigma-Aldrich) at 37 °C and
5%  CO2  for  3  min  and  its  activity  quenched  by  trypsin
inhibitor (Sigma-Aldrich). Cell viability was evaluated using
Trypan blue exclusion (16–910–49; Flow laboratories Irvine,
Scotland, UK), a vital stain. Only cells which excluded trypan
blue were counted.
For immunolocalization, cells were cultured on chamber
slides (NUNC, Rochester, NY). The cells in culture were
observed  under  a  Leica  DM  IRB  microscope  (Leica
Microsystems, Bannockburn, IL) and analyzed with SPOT
Advanced program.
NGF  and  VEGF  determination:  Cell  pellets  obtained  by
centrifugation  of  cell  cultures  (150×  G  for  5  min)  were
homogenized in extraction buffer (10 mM tris-HCl, pH7.4,
100 mM sodium-chloride, 1 mM ethylenediamine-tetraacetic
acid [EDTA], 1 mM ethyleneglycol-tetraacetic acid [EGTA],
1%  triton  X-100,  10%  glycerol,  0.1%  sodium-dodecil-
phosphate,  2  mM  sodium-ortovanadate,  20  mM  sodium-
pyrophosphate, 1 mM sodium-fluoride, 2 μg/ml aprotinin,
1  mM  phenylmethylsulfonyl  fluoride  [PMSF],  1  µg/ml
leupeptin), and supernatant was clarified by centrifugation at
4 °C at 8,000× G for 20 min. The cell concentration of NGF
and VEGF was measured using an ELISA kit (DuoSet Human
β-NGF and Human VEGF kit; R&D Systems, Minneapolis,
MN) following the instructions provided by the manufacturer.
Data are represented as pg protein/µg of protein and all assays
were performed in triplicate.
Single  immunocytochemistry:  Cultured  cells  were  washed
with  phosphate  buffer  saline  (PBS),  fixed  in  4%
paraformaldehid (PFA) for 10 min, washed twice in PBS, and
then permeabilized with PBS containing 0,1% Triton X-100
for  30  min.  Cells  were  then  exposed  to  10%  methanol
containing 3% H2O2 in PBS for 15 min followed by exposure
to BSA (BSA 1%) in PBS for 10 min, and incubated overnight
at 4 °C with the following primary antibodies: polyclonal anti-
TrkA,  monoclonal  anti-VEGF,  monoclonal  anti-p75,  anti-
NGF antibody, all at a concentration of 2 μg/ml. After brief
washes in PBS, cells were incubated with specific biotynilated
secondary antibody and then with immunoperoxidase with the
ABC Vectastain Kit (Vector Laboratories, Inc. Burlingame,
CA) as suggested by the manufacturer’s instructions. Staining
was  developed  by  exposure  to  a  diaminobenzydine  H202
mixture  for  15  min  and  covered  with  mounting  medium.
Staining specificity was assessed by omission of the primary
antibody and by isotypic IgG. Cell immunoreactivity was
evaluated under a 40× objective frame, with a Zeiss Axiophot
microscope (Carl Zeiss S.p.A., Milano, Italy) connected to a
PC and an image analysis program (IAS 2000; Delta Sistemi,
Rome, Italy). The number of VEGF, TrkA, and p75 positivity
cells  in  different  fields  (n=12)  and  different  experimental
groups  (n=4)  was  counted  and  evaluated.  The  results  are
expressed as a percentage of positive control cells.
The effect of NGF on VEGF expression was investigated
after immunoflorescence staining and HCEC were observed
with confocal microscopy (Leica SP 5; Leica Microsystems,
Wetzlar, Germany).
Double immunocytochemistry: To assess the existence of co-
expression of VEGF, TrkA, and p75, fixed cultured cells were
first  immunostained  as  above  with  VEGF,  then
immunostained  with  TrkA  or  p75  following  the  same
procedure. The presence of the second antibody was revealed
with a different biotynilated probe. Cells were finally washed,
mounted with glycerol 50% in PBS (E. Merck, Darmastad,
Germany)  on  a  glass  and  visualized  under  microscope
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1440equipped  with  40×  objective.  All  stained  cells  were  then
examined  with  a  Zeiss  Axhiphot  microscope  and  images
photographed and acquired with an image analysis program
(IAS 2000; Delta Sistemi, Rome, Italy).
Western blotting: Cell pellets obtained by centrifugation of
cell  cultures  (150×  g  for  5  min)  were  homogenized  in
extraction buffer (10 mM tris-HCl, pH7.4, 100 mM sodium-
chloride,  1  mM  ethylenediamine-tetraacetic  acid  [EDTA],
1  mM  ethyleneglycol-tetraacetic  acid  [EGTA],  1%  triton
X-100, 10% glycerol, 0.1% sodium-dodecil-phosphate, 2 mM
sodium-ortovanadate, 20 mM sodium-pyrophosphate, 1 mM
sodium-fluoride,  2  μg/ml  aprotinin,  1  mM
phenylmethylsulfonyl fluoride [PMSF], 1µg/ml leupeptin),
and supernatant was clarified by centrifugation at 4 °C at
8,000× g for 20 min and used for western blotting. Samples
(30 µg of total protein) were dissolved with loading buffer (0.1
M Tris-HCl buffer pH 6.8 containing 0.2 M DTT, 4% SDS,
20% glycerol and 0.1% bromophenol blue), separated by 8%
SDS–PAGE  and  electrophoretically  transferred  to
polyvinylidene fluoride (PVDF) membrane overnight. The
membranes were incubated for 1 h at room temperature with
blocking solution (5% BSA in TTBS 10 mM Tris, pH 7.5,
100 mM NaCl, and 0.1% Tween-20: 10 mM Tris pH 7.5,
100 mM NaCl and 0,1% Tween-20: 10 mM Tris, pH 7.5,
100 mM NaCl, and 0.1% Tween-20: 10 mM Tris, pH 7.5,
100  mM  NaCl,  and  0.1%  Tween-20).  Membranes  were
washed three times for 10 min each time at room temperature
in TTBS followed by incubation at 4 °C with primary antibody
overnight. Membranes were washed three times for 10 min in
TTBS  and  incubated  for  1  h  a  room  temperature  with
secondary antibody anti-rabbit IgG HRP linked.
The blots were developed with ECL chemiluminescent
HRP substrate (Millipore Corporation, Billerica, Ma) as the
chromophore. A personal computer and the public domain
image J software were used to evaluate band density, which
was expressed as arbitrary units of gray level. The image J
software determines the optical density of the bands using a
gray  scale  thresholding  operation.  The  optical  density  of
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) bands
was  used  as  a  normalizing  factor.  For  each  gel/blot  the
normalized values were then expressed as a percentage of the
relative  normalized  controls  and  used  for  statistical
evaluation.
Real time RT–PCR: HCEC treated and untreated with NGF
or ANA were removed with Trypsin/EDTA solution at 37 °C
and 5% CO2 for 3 min and its activity quenched by trypsin
inhibitor. Then the cells were centrifuged at 150× g for 5 min
to obtain a pellet which was then stored a −80 °C until further
use. Total RNA from cells was extracted using a kit, SV Total
RNA  Isolation  System  (Promega  Italia,  Milan,  Italy),
following the instructions provided by the manufacturer. RNA
was quantified by spectrophotometry at 260 and 280 nm and
the samples stored at −80 °C. RNA was converted into cDNA
in a 25 μl reverse transcription reaction containing 1 μg of
total RNA, 1× reverse transcriptase buffer (50 mM Tris-HCl
pH 8.3, 75 mM KCl, 3 mM MgCl2, 10 mM DTT), 0.5 mM
dNTPs, 500 ng oligo (dT)15, 40 U Rnasin RNase inhibitor, and
200 U of M-MLV RT. Reactions were incubated at 42 °C for
60 min, heated at 95 °C for 5 min, then cooled at 4 °C for a
minimum of 5 min and a maximum of 30 min and the sample
stored at −20 °C. RT–PCR was performed using the 7900HT
Fast  Real-Time  PCR  System  (Applied  Biosystems,
Branchburg, NJ), FAM-labeled probe specific for the human
TrkA (Assay ID Hs00176787_m1), FAM-labeled probe for
human  Glyceraldehyde-3-phosphate  dehydrogenase
(GAPDH)  (Assay  ID  Hs99999905_m1)  as  endogenous
control and TaqMan Universal PCR Master Mix (Applied
Biosystem) was included in the reactions.
The cDNA was amplified under the following conditions:
1 cycle at 50 °C for 2 min and at 95 °C for 10 min, followed
by 40 cycles at 95 °C for 15 s and at 60 °C for 1 min. Negative
controls  (without  template)  were  produced  for  each  run.
Experiments were performed in duplicate for each data point.
The amount of mRNA of each gene was calculated using the
standard curve method (following the instructions in User
Bulletin  no.  2;  Applied  Biosystems)  and  adjusted  for  the
expression of GAPDH.
Statistical analysis: Data were obtained by means of ANOVA
(ANOVA)  using  the  Stat  View  package  for  Macintosh
(Abacus Concepts Inc., Berkeley, CA) considering the resting
condition of NGF and VEGF, the effects of NGF, ANA, and
VEGF on HCEC survival at different culture conditions, the
effects of NGF and ANA on VEGF and TrkA expression, as
variables. Differences between groups were determined by the
posthoc Tukey-Kramer test. All results are reported as a mean
±standard error of the mean (S.E.M.). A p-value less than 0.05
was considered significant.
RESULTS
HCECs express NGF receptors: We first investigated whether
HCEC express the NGF-receptors TrkA and p75. As reported
in  Figure  1A-F,  HCECs  express  the  high-affinity  NGF
receptor,  TrkA,  in  resting  condition  (Figure  1A),  TrkA
increases after exposure to NGF (Figure 1B) and decreases
after exposure to ANA (Figure 1C). The low-affinity NGF
receptor, p75, is poorly expressed both in basal condition
(Figure 1D), and after exposure to NGF (Figure 1E) and ANA
(Figure 1F). Western blot analysis and real time PCR also
indicated  that  NGF  increases  and  ANA  decreases  TrkA-
protein expression (Figure 1G,H) and TrkA gene expression
(Figure 1I).
HCECs produce VEGF and NGF and co-express VEGF and
TrkA:  As  shown  in  Figure  1L,  immunoenzymatic
determination of cell pellet cultured for 4 days without NGF
indicated that these cells express 12.4±0.8 pg/mg of VEGF
protein and 4.2±0.3 pg/mg of NGF protein.
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1441Confocal  immunohistochemical  analysis  revealed  that
HCECs express VEGF (red) and TrkA (green) Figure 1M.
NGF promotes HCEC survival in a dose-dependent manner:
A dose–response analysis indicated that NGF exposure for 4
days promotes HCEC survival in a dose-dependent manner.
As reported in Figure 2A, the presence of 1 and 10 ng/ml of
NGF stimulates cell survival, while 100 ng/ml of NGF has no
stimulatory action. This latter effect is not due to HCEC death,
but to inhibition of cells proliferation (data not shown). The
morphological characteristics of HCECs cultured in vitro in
the presence or absence of NGF is shown in Figure 2B-D.
To further investigate the role of NGF on HCEC survival,
these cells were exposed for 4 days to 100 µg/ml ANA, or pre-
immune  serum  (IgG).  As  reported  in  Figure  2E-G,  the
presence of ANA reduces the number of HCECs (Figure 2F),
compared to cells exposed to IgG (Figure 2E). This effect is
statistically significant, as seen in Figure 2G.
Figure  1.  Representative
immnocytochemical  preparations
showing  the  expression  of  NGF-
receptors in HCECs cultured in vitro for
4 days under different conditions. TrkA
expression  in  control  condition  (A),
TrkA  expression  in  cells  exposed  to
NGF (B) and TrkA expression in cells
exposed to ANA (C). Note that NGF
enhances and ANA down-regulates the
expression of TrkA. Panel D illustrate
the expression of the NGF-receptor p75
in control conditions, in cells exposed to
NGF (E), and in cells exposed to ANA
(F). This NGF-receptor is nearly non-
expressed in control HCECs (D), it is
unaffected  after  treatment  with  NGF
(E) or ANA (F). Scale bars: A-F 20 μm.
Panels G and H report the results of
western  blot  and  real-time  PCR  of
HCECs treated with NGF or ANA. As
indicated  in  G  and  H,  compared  to
control,  HCECs  exposed  to  NGF
express more, while these exposed to
ANA  express  less  TrkA  protein.  The
PCR analysis also revealed that NGF
enhances  and  ANA  reduces  the
expression of TrkA gene expression (I).
Panel L reports the amount of NGF and
VEGF  expressed  by  HCECs  under
cultured for 4 days without NGF. This
result  indicates  that  these  cells
constitutively  express,  though
differently, both NGF and VEGF. As
illustrated  in  M,  confocal
immunohistochemical analysis revealed
that HCECs express VEGF (red) and
TrkA (green). Scale bar: M=8 μm.
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1442NGF stimulates the release of VEGF: We next tested the effect
of NGF on cultured HCECs on VEGF expression. As reported
in Figure 3, NGF stimulates the release of VEGF into the
medium (Figure 3A) and in cells (Figure 3B), in a dose-
dependent manner. The effect of VEGF stimulation, both in
cells and medium, is more conspicuous at the concentration
of NGF 10 ng/ml and nearly absent at 100 ng/ml. Thus, like
the effect on cell survival, NGF has no action also on VEGF
stimulation at high concentration NGF has no action, most
probably due to saturation of NGF-receptors expressed by
HCECs.  To  further  investigate  this  effect  HCECs  were
cultured for 4 days in presence of different concentration of
Figure 2. This figure reports the effect
of NGF on HCEC survival. A: The result
of  a  time-course  analysis  of  HCECs
exposed for 4 days to culture medium
alone or with 1 ng, 10 ng, or 100 ng of
NGF/ml, revealed that at 1 and 10 ng,
NGF enhances cell survival, while 100
ng/ml  of  NGF  down-regulates  cell
survival,  compared  to  control,
(*p<0.05). B-D illustrate the structural
aspect of these cells exposed to medium
alone (B), 10 ng/ml (C), and 100 ng/ml
of NGF (D). Note the decreased in cell
number in D. Panels E and F illustrate
the effect of endogenous NGF inhibition
by  ANA  on  HCEC  survival.  The
supplementation of ANA in the culture
medium at concentration of 100 ng/ml
of  medium,  significantly  (*p<0.05),
reduces the number of cells after 4 days
in vitro (F), compared to control (E).
This effect was statistically significant
(G). Scale bars: B-F=25μm.
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1443ANA. The results shown in Figure 3C,D, indicated that ANA
has  no  effect  on  VEGF  release  into  the  medium  at  all
concentrations tested (Figure 3C), while it exerts a significant
down-regulation of VEGF expression in cell pellet at the
concentration of 100 ng/ml (Figure 3D). This latter effect
might be due to the inhibition of the biologic activity of NGF
and NGF-receptors constitutively present in HCECs.
Confocal microscope analysis of HCECs also revealed
that NGF at 10 ng/ml enhances the expression of VEGF in the
cells,  Figure  3F,  while  100  μg/ml  of  ANA  reduces  the
expression of VEGF, Figure 3G, compared to untreated cells,
Figure 3E.
The effect of NGF on HCEC survival is different from the
effect of VEGF: Because NGF and VEGF seem to have similar
effects on endothelial cell survival, we next tested the effect
of VEGF on HCEC survival at 1, 10 and 100 ng/ml of medium
[16,19].  As  reported  in  Figure  4,  a  dose–response  study
indicated that VEGF enhances the survival of HCEC in a dose-
dependent manner (Figure 4A), exerting its highest effect at
the dose of 100 ng/ml of medium. Differently from NGF,
VEGF has no inhibitory action at high concentration. The
survival  and  morphological  aspect  of  HCECs  cultured  in
presence of medium only and 100 ng/ml of VEGF of medium
are illustrated in Figure 4B,C.
DISCUSSION
In this study we investigated the role and the effects of NGF
on  a  human  corneal  endothelial  cell  culture.  Our  results
Figure 3. Dose–response effect of NGF
and  ANA  on  VEGF  expression  in
culture  medium  and  cell  pellet  of
HCECs after supplementation of 1, 10,
and 100 ng/ml of NGF or ANA at 1, 10
and  100  μg/ml  of  medium.  NGF
enhances the presence of VEGF both in
the  medium  and  in  pellet  at
concentration of 1 or 10 ng/ml of NGF.
At  100  ng/ml  NGF  has  an  inhibitor
action  on  VEGF  expression.  ANA
exposure  has  no  effect  on  the
concentration of VEGF in the medium
(C), but significantly reduces (*p<0.05)
VEGF  presence  in  the  pellet  at
concentration  of  100  ug/ml  (D).
Confocal microscopic analysis of cells
exposed to 10 ng/ml of NGF and 100 µg/
ml of ANA are illustrated, respectively
in  F  and  G.  Note  the  enhanced
expression of VEGF after exposure of
NGF (F) and the down-regulation after
exposure  of  ANA  (G),  compared  to
control  (E).  Arrows  point  to  VEGF
immunopositivity.  Scale  bars:  E-
G=15μm.
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1444indicate that the human corneal endothelial cell line B4G12
produces  and  releases  NGF  and  that  NGF  enhances  the
expression  of  VEGF  and  the  high-affinity  NGF-receptor,
TrkA, but not the low-affinity NGF-receptor, p75. It is well
known that the TrkA/p75 ratio regulates cell fate and function,
with  p75  being  pro-apoptotic  and  TrkA  promoting  cell
survival in different cell types [8,28]. Our evidence of NGF
promoting TrkA –but not p75– expression in HCEC may
explain  the  observation  that  NGF  promotes  HCEC  cell
survival in a dose-dependent manner, while the neutralizing
NGF antibody has the opposite effect. The expression of NGF
and both its receptors by the same cell line suggests that these
effects are regulated by an autocrine or paracrime mechanism.
It is plausible to hypothesize that these beneficial effects
physiologically  occur  following  intra-ocular  injuries  (as
previously  demonstrated  in  experimental  iridectomy)  to
protect  the  corneal  endothelium,  in  line  with  previously
published data on NGF endothelial gene transfer and NGF
effects during corneal epithelial injury and wound healing
[11,29].
The effects of NGF on corneal endothelial cell survival
may also be synergistic with those of other growth factors
physiologically present and/or released following intra-ocular
injuries.  Among  these  growth  factors,  in  this  study  we
investigated the role of VEGF since increasing evidence is
demonstrating a direct partnership of NGF and VEGF in the
regulation of cell function, healing and immune mechanisms.
VEGF  has  been  primarily  known  as  an  angiogenesis
mediator, however increasing evidence is now also showing
that VEGF might play relevant roles in cell survival. In line
with these recent updates on VEGF function, our in vitro data
demonstrates  a  survival-promoting  effects  of  VEGF  on
HCECs.  It  may  also  be  interesting  to  speculate  that  this
survival-promoting effect of VEGF could be amplified in vivo
by  an  autocrine/paracrine  NGF  stimulation  of  VEGF
production and release in the anterior chamber of the eye.
Figure 4. Dose–response analysis on the
effect of VEGF on HCEC survival. The
results  indicated  that  VEGF
supplementation  into  culture  medium
for 4 days enhances HCEC survival at 1,
10, and 100 ng/ml medium, compared to
control  (A;  *p<0.05).  The
morphological  aspect  of  HCECs
exposed to control medium without and
with 100 ng/ml of VEGF is shown in B
and  C,  respectively.  Scale  bars:  B,
C=25μm.
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1445Based on this data, another fascinating hypothesis that
can be drawn involves an active role of both NGF and VEGF
on the pathophysiological mechanisms behind the immune
reactions of the anterior chamber of the eye. In fact, it is well
known that the anterior chamber represents a site of immune
privilege  (the  so-called  ACAID  or  Anterior  Chamber
Associated  Immune  Deviation)  in  which,  to  date,  the
endothelium  has  not  been  considered  to  play  an  active
immunomodulatory action.
If  confirmed,  this  presumed  endothelial-driven
immunomodulation could be related to our evidence on VEGF
in HCECs, since VEGF has been recently demonstrated to
play immunomodulatory roles, including the maturation of
granulocyte-macrophage progenitors and on the inhibition of
dendritic cells’ development into mature, antigen presenting,
dendritic cells [30]. In addition, NGF has also been shown to
play an important role in regulating the immune response.
Specifically,  NGF  modulates  the  immune  reaction  form
predominantly Th1 to Th2 type and exerts a relevant anti-
inflammatory action.
The fact that both VEGF and NGF are expressed by
corneal endothelial cells supports the hypothesis that these
growth  factors  are  implicated  in  the  physiopathology  of
corneal homeostasis. Moreover, the observation that ANA
reduces  the  number  of  HCECs  and  down-regulates  the
expression  of  TrkA  and  VEGF,  further  supports  the
hypothesis  that  NGF  plays  a  critical  action  on  corneal
homeostasis  and  healing,  most  likely  acting  not  only  on
corneal epithelial cells –as already widely demonstrated by
our group and by others– but also on endothelial cells.
Why ANA is unable to alter the basal expression of TrkA
and  VEGF  is  not  known.  One  possibility  is  that  other
mechanisms are involved in the regulation of TrkA and VEGF
expression by corneal endothelial cells.
In conclusion, the results of this study provide additional
evidence that human corneal endothelial cells are NGF target
cells that express both NGF receptors. An autocrine/paracrine
mechanism of NGF on these receptors may trigger not only
the  well  known  effects  of  NGF  on  corneal  healing  and
survival, but also initiate more complex signaling pathways
involving  other  growth  factors  (such  as  VEGF)  with
immunomodulatory roles.
These observations might facilitate the development of
further pharmacological approaches of NGF-based therapy
and possibly improve the prognosis of corneal endothelial
diseases and the outcomes of corneal transplantation. Taken
together  our  findings  suggest  that  NGF  eye  drop
administration, might contribute not only to epithelial cells
proliferation,  but  also  to  the  maintenance  of  corneal
endothelial function [10,31].
ACKNOWLEDGMENTS
This  study  was  supported  by  PRIN  prot.  N°
2007AF3XH4_005 to L. Aloe, and by “Fondazione Cassa di
Risparmio di Roma” and “Ministero della Salute” Grant N°
RF-FGB-2005–150198.  We  wish  to  thank  Dr.  Valtink
Monika for providing the cell line B4G12 of human corneal
endothelial cells, and Dr. Fulvio Florenzano for microscopic
confocal analysis.
REFERENCES
1. Levi-Montalcini R. The nerve growth factor 35 years later.
Science 1987; 237:1154-62. [PMID: 3306916]
2. Aloe L and Calza L. editors. NGF and Related Molecules in
Health and Disease. Progr Brain Res Elsevier 2004.
3. Oku H, Ikeda T, Honma Y, Sotozono C, Nishida K, Nakamura
Y, Kida T, Kinoshita S. Gene expression of neurotrophins and
their high-affinity Trk receptors in cultured human Müller
cells. Ophthalmic Res 2002; 34:38-42. [PMID: 11834883]
4. Siliprandi R, Canella R, Carmignoto G. Nerve growth factor
promotes functional recovery of retinal ganglion cells after
ischemia.  Invest  Ophthalmol  Vis  Sci  1993;  34:3232-45.
[PMID: 8225858]
5. Carmignoto G, Maffei L, Candeo P, Canella R, Comelli C.
Effect of NGF on the survival of rat retinal ganglion cells
following optic nerve section. J Neurosci 1989; 9:1263-72.
[PMID: 2467970]
6. Lambiase A, Centofanti M, Micera A, Manni GL, Mattei E, De
Gregorio A, de Feo G, Bucci MG, Aloe L. Nerve growth
factor (NGF) reduces and NGF antibody exacerbates retinal
damage  induced  in  rabbit  by  experimental  ocular
hypertension.  Graefes  Arch  Clin  Exp  Ophthalmol  1997;
235:780-5. [PMID: 9439971]
7. Lenzi L, Coassin M, Lambiase A, Bonini S, Amendola T, Aloe
L. Effect of exogenous administration of nerve growth factor
in the retina of rats with inherited retinitis pigmentosa. Vision
Res 2005; 45:1491-500. [PMID: 15781068]
8. Meakin SO, Shooter EM. The nerve growth factor family of
receptors.  Trends  Neurosci  1992;  15:323-31.  [PMID:
1382329]
9. Lambiase A, Rama P, Bonini St, Caprioglio G, Aloe L. Topical
treatment with nerve growth factor for corneal neurotrophic
ulcers. N Engl J Med 1998; 338:1174-80. [PMID: 9554857]
10. Lambiase A, Manni L, Bonini S, Rama P, Micera A, Aloe L.
Nerve growth factor promotes corneal healing: structural,
biochemical,  and  molecular  analyses  of  rat  and  human
corneas. Invest Ophthalmol Vis Sci 2000; 41:1063-9. [PMID:
10752942]
11. Cellini M, Bendo E, Bravetti GO, Campos EC. The use of nerve
growth  factor  in  surgical  wound  healing  of  the  cornea.
Ophthalmic Res 2006; 38:177-81. [PMID: 16679804]
12. Ferrara N, Davis-Smyth T. The biology of vascular endothelial
growth factor. Endocr Rev 1997; 18:4-25. [PMID: 9034784]
13. Sondell M, Lundborg G, Kanje M. Vascular endothelial growth
factor  has  neurotrophic  activity  and  stimulates  axonal
outgrowth,  enhancing  cell  survival  and  Schwann  cell
proliferation in the peripheral nervous system. J Neurosci
1999; 19:5731-40. [PMID: 10407014]
14. Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N,
Akita J, Samuelsson SJ, Robinson GS, Adamis AP, Shima
DT. Vascular endothelial growth factor-A is a survival factor
for retinal neurons and a critical neuroprotectant during the
Molecular Vision 2010; 16:1439-1447 <http://www.molvis.org/molvis/v16/a157> © 2010 Molecular Vision
1446adaptive  response  to  ischemic  injury.  Am  J  Pathol  2007;
171:53-67. [PMID: 17591953]
15. Saint-Geniez  M,  Maharaj  AS,  Walshe  TE,  Tucker  BA,
Sekiyama E, Kurihara T, Darland DC, Young MJ, D'Amore
PA.  Endogenous  VEGF  is  required  for  visual  function:
evidence  for  a  survival  role  on  muller  cells  and
photoreceptors.  PLoS  ONE  2008;  3:e3554.  [PMID:
18978936]
16. Cursiefen C, Chen L, Saint-Geniez M, Hamrah P, Jin Y, Rashid
S, Pytowski B, Persaud K, Wu Y, Streilein JW, Dana R.
Nonvascular  VEGF  receptor  3  expression  by  corneal
epithelium maintains avascularity and vision. Proc Natl Acad
Sci USA 2006; 103:11405-10. [PMID: 16849433]
17. Lazarovici P, Marcinkiewicz C, Lelkes PI. Cross talk between
the cardiovascular and nervous systems: neurotrophic effects
of vascular endothelial growth factor (VEGF) and angiogenic
effects of nerve growth factor (NGF)-implications in drug
development. Curr Pharm Des 2006; 12:2609-22. [PMID:
16842161]
18. Steinle JJ, Granger HJ. Nerve growth factor regulates human
choroidal,  but  not  retinal,  endothelial  cell  migration  and
proliferation.  Auton  Neurosci  2003;  108:57-62.  [PMID:
14614965]
19. Shakiba  Y,  Mansouri  K,  Arshadi  D,  Rezaei  N.  Corneal
neovascularization: molecular events and therapeutic options.
Recent Pat inflamm Allergy Drug Discov 2009; 3:221-31.
[PMID: 14614965]
20. Nico B, Mangieri D, Benagiano V, Crivellato E, Ribatti D.
Nerve growth factor as an angiogenic factor. Microvasc Res
2008; 75:135-41. [PMID: 17764704]
21. Kim  TI,  Chung  JL,  Hong  JP,  Min  K,  Seo  KY,  Kim  EK.
Bevacizumab application delays epithelial healing in rabbit
cornea. Invest Ophthalmol Vis Sci 2009; 50:4653-9. [PMID:
19458331]
22. Kim  EC,  Lee  WS,  Kim  MS.  .  The  Inhibitory  Effects  of
Bevacizumab  Eyedrops  on  NGF  Expression  and  Corneal
Wound Healing in Rats. Invest Ophthalmol Vis Sci. 2010
[PMID: 19458331]
23. Götze  T,  Valtink  M,  Nitschke  M,  Gramm  S,  Hanke  T,
Engelmann K, Werner C. Cultivation of an immortalized
human corneal endothelial cell population and two distinct
clonal subpopulations on thermo-responsive carriers. Graefes
Arch  Clin  Exp  Ophthalmol  2008;  246:1575-83.  [PMID:
18696098]
24. Bocchini V, Angeletti PU. The nerve growth factor: purification
as a 30,000-molecular-weight protein. Proc Natl Acad Sci
USA 1969; 64:787-94. [PMID: 4982360]
25. Stoeckel K, Gagnon C, Guroff G, Thoenen H. Purification of
nerve growth factor antibodies by affinity chromatography. J
Neurochem 1976; 26:1207-11. [PMID: 819632]
26. Chandler  CE,  Parsons  LM,  Hosang  M,  Shooter  EM.  A
monoclonal  antibody  modulates  the  interaction  of  nerve
growth  factor  with  PC12  cells.  J  Biol  Chem  1984;
259:6882-9. [PMID: 6327698]
27. Valtink M, Gruschwitz R, Funk RH, Engelmann K. Two clonal
cell lines of immortalized human corneal endothelial cells
show either differentiated or precursor cell characteristics.
Cells Tissues Organs 2008; 187:286-94. [PMID: 18196893]
28. Casaccia-Bonnefil P, Gu C, Chao MV. Neurotrophins in cell
survival/death  decisions.  Adv  Exp  Med  Biol  1999;
468:275-82. [PMID: 10635036]
29. Lambiase  A,  Bonini  S,  Aloe  L,  Rama  P,  Bonini  S.  Anti-
inflammatory and healing properties of nerve growth factor
in  immune  corneal  ulcers  with  stromal  melting.  Arch
Ophthalmol 2000; 118:1446-9. [PMID: 11030834]
30. Johnson B, Osada T, Clay T, Lyerly H, Morse M. Physiology
and  therapeutics  of  vascular  endothelial  growth  factor  in
tumor immunosuppression. Curr Mol Med 2009; 9:702-7.
[PMID: 19689297]
31. Lambiase A, Bonini S, Micera A, Rama P, Bonini S, Aloe L.
Expression of nerve growth factor receptors on the ocular
surface  in  healthy  subjects  and  during  manifestation  of
inflammatory  diseases.  Invest  Ophthalmol  Vis  Sci  1998;
39:1272-5. [PMID: 9620090]
Molecular Vision 2010; 16:1439-1447 <http://www.molvis.org/molvis/v16/a157> © 2010 Molecular Vision
The print version of this article was created on 26 July 2010. This reflects all typographical corrections and errata to the article
through that date. Details of any changes may be found in the online version of the article.
1447